LOCALLY ADVANCED BREAST CANCER

This study tests a new drug, palazestrant, combined with ribociclib against the standard letrozole with ribociclib for people with ER+, HER2- advanced breast cancer that has not been treated before. About 1,000 adults with locally advanced or metastatic breast cancer will take pa…

This study tests two experimental drugs (BNT323 and BNT327) together in people with advanced breast cancer that has spread or cannot be removed by surgery. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of HER2…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune system's response to the drug pembrolizumab in people with advanced triple-negative breast cancer. About 30 participants will either receive the combination or pembrolizumab alone. The goal …

This study tests whether adding the drug pyrotinib to standard trastuzumab therapy can further reduce the chance of breast cancer returning in women with HER2-positive breast cancer who still have cancer cells after initial chemotherapy and anti-HER2 treatment. About 316 women wi…

This phase 3 trial tests a new drug called HRS-8080 against standard treatments chosen by doctors for women with advanced breast cancer that has worsened after hormone therapy. About 240 women aged 18-75 will be randomly assigned to receive either HRS-8080 or another treatment. T…

This study tests a new drug called FWD1802 in people with a specific type of advanced breast cancer (ER+/HER2-). The goal is to find a safe dose and see if it can shrink tumors. About 99 women with cancer that has spread or cannot be removed by surgery will take part.

This study tests a new drug called OP-1250 (Palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. About 190 adults will receive one of four drug combinations to find the safest dose and understand side…

This early-phase study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple-negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants with advance…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The cancer must have a specific gene change (PIK3CA mutation) and be hormone receptor-positive and HER2-negative. About …

This study tests whether a 24-week exercise program (aerobic and strength training, 3 times a week) can help prevent breast cancer from returning in people with early-stage breast cancer. About 2,156 participants who have completed surgery and any chemotherapy or radiation will t…

This study compares a contrast-enhanced digital mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy before surgery. About 30 women with locally advanced breast cancer will get 1-2 of these s…

This study tests whether combining the drug memantine with a structured exercise program can improve memory and thinking in breast cancer patients undergoing chemotherapy. About 90 women with early-stage breast cancer will be split into three groups: memantine plus exercise, mema…

This study is testing whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It includes up to 5,000 participants with early-stage or locally advanced breast cancer. The goal is to use MRI scans and tissue…